NCO-48 / Nucorion, Ligand - LARVOL DELTA

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B (clinicaltrials.gov) - P1 | N=21 | Completed | Sponsor: Nucorion Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed

Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation

PHASE 1b STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-HEPATITIS B VIRUS (HBV) ACTIVITY OF NCO-48 FUMARATE (NCO48F), A NOVEL LIVER-TARGETED PRODRUG (LTP) OF TENOFOVIR (TFV), IN TREATMENT-NAIVE ADULTS WITH CHRONIC HBV INFECTION (AASLD 2022) - "NCO-48F is a promising agent for the treatment of HBV, demonstrating excellent safety and PK properties, and declines in HBV DNA comparable to TAF."

Clinical • P1 data • PK/PD data • Hematological Disorders • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B (clinicaltrials.gov) - P1 | N=21 | Active, not recruiting | Sponsor: Nucorion Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2022 ➔ Dec 2022 | Trial primary completion date: Apr 2022 ➔ Sep 2022

Enrollment closed • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

[VIRTUAL] SINGLE-DOSE PHARMACOKINETICS AND SAFETY OF NCO-48 FUMARATE, A NOVEL LIVER-TARGETED PRODRUG (LTP) OF TENOFOVIR (TFV) (AASLD 2021) - P1 | "NCO-48F is a promising agent for the treatment of HBV, demonstrating excellent PK properties after a single dose, and is currently in a multiple-dose clinical trial in HBV patients (NCT04629976)."

Clinical • PK/PD data • Dyspepsia • Hematological Disorders • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Nucorion Pharmaceuticals, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hepatitis B • Hepatology • Infectious Disease

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Nucorion Pharmaceuticals, Inc.

Clinical • New P1 trial • Hepatitis B • Hepatology • Infectious Disease

Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects (clinicaltrials.gov) - P1; N=48; Completed; Sponsor: Nucorion Pharmaceuticals, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Hepatitis B • Hepatology • Infectious Disease

Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects (clinicaltrials.gov) - P1; N=48; Active, not recruiting; Sponsor: Nucorion Pharmaceuticals, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Hepatitis B • Infectious Disease

Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Nucorion Pharmaceuticals, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Chronic Kidney Disease • Hepatitis B • Infectious Disease • Renal Disease